Coagulopathy Reversal (Nonwarfarin Agents)

Coagulopathy Reversal (Nonwarfarin Agents) is a topic covered in the 5-Minute Emergency Consult.

To view the entire topic, please or purchase a subscription.

Emergency Central is a collection of disease, drug, and test information including 5-Minute Emergency Medicine Consult, Davis’s Drug, McGraw-Hill Medical’s Diagnosaurus®, Pocket Guide to Diagnostic Tests, and MEDLINE Journals created for emergency medicine professionals. Explore these free sample topics:

Emergency Central

-- The first section of this topic is shown below --



  • Patient on anticoagulant medications with minor, major, or clinically significant bleeding needing close monitoring +/− anticoagulant reversal
  • Anticoagulant medication
    • Indirect inhibitors of thrombin
      • Unfractionated heparin (UFH)
      • Low–molecular-weight heparin (LMWH)
        • Enoxaparin
        • Dalteparin
        • Tinzaparin
    • Anti-platelet agents
      • Aspirin
      • Clopidogrel hydrogen sulfate (Plavix)
    • Factor Xa inhibitors (FXa inhibitors)
      • Fondaparinux (Arixtra)
      • Rivaroxaban (Xarelto)
    • Direct thrombin inhibitors (DTIs)
      • Argatroban
      • Bivalirudin (Angiomax)
      • Dabigatran (Pradaxa)
      • Hirudin derivatives
        • Desirudin
        • Lepiruden (Refludan)

Pediatric Considerations
  • Heparin and LMWH are the most commonly utilized anticoagulants beyond warfarin
  • Routine use of DTIs is being studied

Geriatric Considerations
Excretion primarily renal with FXa inhibitors, Dabigatran, and Hirudin derivatives necessitating caution with impaired renal function


Incidence and Prevalence Estimates
  • Indirect inhibitors of thrombin
    • Up to 1/3 patients develop bleeding complication
    • 2–6% of bleeding is major
  • Anti-platelet agents
    • >300 over-the-counter medications contain aspirin
    • Conflicting studies regarding increased hematoma expansion and mortality
  • FXa Inhibitors
    • Unknown
  • DTIs
    • Unknown


  • Indirect inhibitors of thrombin
    • Combines with antithrombin III to inactivate activated FXa and also inhibits thrombin
    • LMWH has a reduced ability to inactivate thrombin
    • Half-life is dose dependent (30–150 min), can be up to 8 hr with LMWH
  • Anti-platelet agents
    • Inactivates cyclooxygenase-1 (COX-1) preventing formation of thromboxane A2, which inactivates platelets
    • Single dose suppresses for 1 wk
    • New platelet production recovers 10%/day
    • Patients may manifest normal hemostasis with as few as 20% platelets with normal COX1 activity
    • Aspirin half-life 15–30 min
    • Clopidogrel half-life 8 hr
  • FXa inhibitors
    • Binds to antithrombin III, catalyzing FXa inhibition
    • No direct inhibitory effect on thrombin
    • Half-life 12–21 hr in normal renal function
  • DTIs
    • Competitively targets active site of thrombin +/− exosite (substrate binding site)
    • Half-life long with dabigatran (14–17 hr) and short with others (20–45 min)

-- To view the remaining sections of this topic, please or purchase a subscription --